Announces the Appointment of Dr Liz Holmes as Chief Medical Officer Newly established role at further strengthens leadership team and supports global growth Dr Liz Holmes’ rare disease and oncology ...

Cycle Pharmaceuticals Ltd ("Cycle"), a dynamic leader in developing rare disease therapies, today reaffirmed its proposal to acquire all of the issued and outstanding shares of Vanda Pharmaceuticals, ...

GSK said it is paying $2.1 billion upfront for Cambridge, Massachusetts-based Affinivax ... That rise came despite the approval of Merck & Co's 15-valent Vaxneuvance in July 2021, which has ...

"VERVE-101 is a first-in-class gene editing medicine that we have designed to make a single spelling change in liver DNA to permanently turn off a disease-causing gene," said the Cambridge ...

Merck KGaA cut its mid-term sales growth target for its health-care division after a number of high-profile drug trial ...

German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level that is likely to hold. Keytruda remains a key revenue driver, with potential for ...

Erratum: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, ...

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively. ALAMEDA ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...